Clinical Trials
428 trialsRadiosurgery Before Surgery for the Treatment of Brain Metastases
Emory University
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Vandevol
University Hospital, Lille
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
FORTE
University of Turin, Italy
IFM2014-04
University Hospital, Lille
RZD
Hackensack Meridian Health
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
Auto-LLC 2001
University Hospital, Caen
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
Zhejiang Cancer Hospital
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients
Aga Khan University
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
REDEX
Leiden University Medical Center
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
IFM2010-02
University Hospital, Lille
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
LyMa101
The Lymphoma Academic Research Organisation
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Dex-Fib
University of Miami
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
MUKEight
University of Leeds
Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
Massachusetts Eye and Ear Infirmary
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
M.D. Anderson Cancer Center
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute
High Dose Carfilzomib for Newly Diagnosed Myeloma
Memorial Sloan Kettering Cancer Center
SINE
University of Chicago
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Dana-Farber Cancer Institute
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
GWT-TUD GmbH
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity
Loma Linda University
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
Barbara Ann Karmanos Cancer Institute
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone
Zhejiang Cancer Hospital